News
ARMP
--
0.00%
--
Nvidia’s $40 billion Arm acquisition could be targeted by Chinese regulators, analysts say
China's Ministry of Commerce (MOFCOM) and China's State Administration for Market Regulation (SAMR) could get in the way Nvidia's Arm acquisition.
CNBC.com · 3d ago
Tech investors predict Nvidia's $40 billion Arm acquisition will be blocked
Nvidia's $40 billion acquisition of chip designer Arm will most likely be blocked, according to two technology investors in Britain.
CNBC.com · 3d ago
SoftBank’s Arm sale hits a snag as UK opposition party warns of risk to jobs and digital sovereignty
Arm's chips are used by companies around the globe to power millions of electrical devices.
CNBC.com · 3d ago
Arm CEO expects regulators to ‘take a good look’ at the Nvidia deal
Simon Segars, the chief executive of Arm, said he expects regulators to "take a good look" at the company's deal with U.S. chipmaker Nvidia.
CNBC.com · 4d ago
Nvidia's Arm takeover sparks concern in the UK
British chip designer Arm is set to be acquired by rival Nvidia for $40 billion but Hermann Hauser, who helped to set up Arm, isn't happy about it.
CNBC.com · 4d ago
Microsoft-backed Graphcore calls on UK regulator to block Nvidia’s Arm acquisition
Hermann Hauser, who helped to create Arm in 1990, told CNBC that Graphcore has opposed the deal in a "major submission."
CNBC.com · 4d ago
Nvidia's Arm takeover sparks concern in the UK
British chip designer Arm is set to be acquired by rival Nvidia for $40 billion but Hermann Hauser, who helped to set up Arm, isn't happy about it.
CNBC.com · 02/19 10:50
Armata Pharmaceuticals (ARMP) Gets a Buy Rating from Ladenburg Thalmann & Co.
SmarterAnalyst · 02/09 11:45
Microsoft-backed Graphcore calls on UK regulator to block Nvidia’s Arm acquisition
Graphcore has objected to Nvidia's $40 billion acquisition of Arm Holdings, according to a co-founder of the British chipmaker.
CNBC.com · 02/05 15:08
Analysts Offer Insights on Healthcare Companies: and Armata Pharmaceuticals (ARMP)
There's a lot to be optimistic about in the Healthcare sector as 1 analysts just weighed in on and Armata Pharmaceuticals (ARMP) with bullish sentiments.
SmarterAnalyst · 02/01 09:03
Insider Trends: 90-Day Insider Selling Trend at Armata Pharmaceuticals Slowed with Acquisition of Shares
MT Newswires · 01/28 13:49
DJ Armata Pharmaceuticals to Get $20M Investment From Innoviva
Dow Jones · 01/27 14:19
Armata announces capital raise of $20M
Armata Pharma (ARMP) has entered into a securities purchase agreement to sell its common stock and warrant securities to Innoviva Strategic Opportunities, a wholly-owned subsidiary of Innoviva (INVA) with gross
Seekingalpha · 01/27 13:53
BRIEF-Armata Pharmaceuticals Announces $20 Million Investment To Support Advancement Of The Company's Bacteriophage Development Programs
reuters.com · 01/27 12:19
Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs
, /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today a...
PR Newswire - PRF · 01/27 12:01
Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it ha...
PR Newswire · 01/27 12:01
Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it ha...
PR Newswire · 01/27 12:01
Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors
, /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today ...
PR Newswire - PRF · 12/09/2020 12:30
Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Robi...
PR Newswire · 12/09/2020 12:30
Armata Pharmaceuticals Announces the Addition of Robin C. Kramer to its Board of Directors
PR Newswire · 12/09/2020 12:30
Webull provides a variety of real-time ARMP stock news. You can receive the latest news about Armata Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ARMP
Armata Pharmaceuticals, Inc., formerly AmpliPhi Biosciences Corporation, is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates are AB-SA01 and AB-PA01.